MoonLake Immunotherapeutics (MLTX)
Automate Your Wheel Strategy on MLTX
With Tiblio's Option Bot, you can configure your own wheel strategy including MLTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MLTX
- Rev/Share 0.0016
- Book/Share 5.6563
- PB 2.4688
- Debt/Equity 0.2142
- CurrentRatio 16.6471
- ROIC -0.4611
- MktCap 879057475.0
- FreeCF/Share -2.6352
- PFCF -5.2714
- PE -4.9488
- Debt/Assets 0.1647
- DivYield 0
- ROE -0.4161
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | MLTX | H.C. Wainwright | Neutral | Buy | -- | $30 | Nov. 3, 2025 |
| Downgrade | MLTX | H.C. Wainwright | Buy | Neutral | -- | -- | Oct. 2, 2025 |
| Downgrade | MLTX | Goldman | Buy | Neutral | -- | $7 | Oct. 1, 2025 |
| Downgrade | MLTX | Citigroup | Buy | Neutral | -- | $5 | Sept. 30, 2025 |
| Downgrade | MLTX | Wolfe Research | Outperform | Underperform | -- | $2 | Sept. 30, 2025 |
| Downgrade | MLTX | BTIG Research | Buy | Neutral | -- | -- | Sept. 29, 2025 |
| Downgrade | MLTX | Jefferies | Buy | Hold | -- | $8 | Sept. 29, 2025 |
| Downgrade | MLTX | RBC Capital Mkts | Outperform | Sector Perform | -- | $10 | Sept. 29, 2025 |
| Downgrade | MLTX | Stifel | Buy | Hold | -- | $13 | Sept. 29, 2025 |
| Initiation | MLTX | Rothschild & Co Redburn | -- | Neutral | -- | $65 | July 28, 2025 |
News
MoonLake Immunotherapeutics' (MLTX) Reported Phase 3 Trial Data for Sole Drug Candidate, 90% Stock Crash Triggers Investor Suit -- Hagens Berman
Published: November 27, 2025 by: Newsfile Corp
Sentiment: Neutral
MLTX Investors with Losses Encouraged to Contact the Firm San Francisco, California--(Newsfile Corp. - November 27, 2025) - MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotechnology company, has been hit with a securities fraud class action lawsuit after its share price plummeted nearly 90% in a single day. The sharp decline was triggered by the release of disappointing Phase 3 trial results for its lead and only drug candidate, sonelokimab (SLK).
Read More
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
Published: November 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 10, 2024 and September 29, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before December 15, 2025.
Read More
MLTX DEADLINE: ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages MoonLake Immunotherapeutics Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - MLTX
Published: November 26, 2025 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - November 26, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline. SO WHAT: If you purchased MoonLake common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Deadline Alert: MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: November 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming December 15, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) common stock between March 10, 2024 and September 29, 2025, inclusive (the “Class Period”).
Read More
MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: November 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired MoonLake securities between March 10, 2024 and September 29, 2025, both dates inclusive (the “Class Period”).
Read More
MLTX Class Action Reminder – Robbins LLP Reminds MoonLake Immunotherapeutics Stockholders of the Opportunity to Lead the Class Action Lawsuit
Published: November 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Company: MoonLake Immunotherapeutics (MLTX) is a Swiss clinical-stage biotechnology company focused on inflammatory diseases driven by interleukin-17 (IL-17), particularly in dermatology and rheumatology. What is the class period?
Read More
MoonLake Immunotherapeutics' (MLTX) Reported Phase 3 Trial Data for Sole Drug Candidate, 90% Stock Crash Triggers Investor Suit -- Hagens Berman
Published: November 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotechnology company, has been hit with a securities fraud class action lawsuit after its share price plummeted nearly 90% in a single day. The sharp decline was triggered by the release of disappointing Phase 3 trial results for its lead and only drug candidate, sonelokimab (SLK).
Read More
Investors in MoonLake Immunotherapeutics Should Contact The Gross Law Firm Before December 15, 2025 to Discuss Your Rights – MLTX
Published: November 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX).
Read More
MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: November 21, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Nov. 21, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) have opportunity to lead the securities fraud class action lawsuit.
Read More
MoonLake Immunotherapeutics' (MLTX) Reported Phase 3 Trial Data for Sole Drug Candidate, 90% Stock Crash Triggers Investor Suit -- Hagens Berman
Published: November 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotechnology company, has been hit with a securities fraud class action lawsuit after its share price plummeted nearly 90% in a single day. The sharp decline was triggered by the release of disappointing Phase 3 trial results for its lead and only drug candidate, sonelokimab (SLK).
Read More
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - MLTX
Published: November 21, 2025 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - November 21, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline. SO WHAT: If you purchased MoonLake common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
Published: November 21, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in MoonLake between March 10, 2024 and September 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Nov. 21, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Reuters Research Inc. ("MoonLake" or the …
Read More
MLTX INVESTORS: BFA Law Reminds MoonLake Immunotherapeutics Investors with Losses to Contact the Firm Before the Imminent December 15 Securities Class Action Deadline
Published: November 20, 2025 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - November 20, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/moonlake-immunotherapeutics-class-action-lawsuit.
Read More
ROSEN, LEADING INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - MLTX
Published: November 20, 2025 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - November 20, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline. SO WHAT: If you purchased MoonLake common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
Published: November 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 20, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 10, 2024 and September 29, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before December 15, 2025.
Read More
MLTX LAWSUIT: MoonLake Immunotherapeutics Investors are Notified to Contact BFA Law about the Filed Securities Fraud Class Action and Important December 15 Deadline
Published: November 19, 2025 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - November 19, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/moonlake-immunotherapeutics-class-action-lawsuit.
Read More
Deadline Alert: MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: November 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming December 15, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) common stock between March 10, 2024 and September 29, 2025, inclusive (the “Class Period”).
Read More
MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: November 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired MoonLake securities between March 10, 2024 and September 29, 2025, both dates inclusive (the “Class Period”).
Read More
Lost Money on MoonLake Immunotherapeutics (MLTX)? Contact Levi & Korsinsky Before December 15, 2025 to Join Class Action
Published: November 19, 2025 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - November 19, 2025) - If you suffered a loss on your MoonLake Immunotherapeutics (NASDAQ: MLTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/moonlake-lawsuit-submission-form?prid=178166&wire=5&utm_campaign=12 or contact Joseph E. Levi, Esq.
Read More
MLTX CLASS NOTICE: BFA Law Alerts MoonLake Immunotherapeutics Investors of the Pending Securities Fraud Class Action and Upcoming December 15 Deadline
Published: November 18, 2025 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - November 18, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/moonlake-immunotherapeutics-class-action-lawsuit.
Read More
MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman
Published: November 18, 2025 by: PRNewsWire
Sentiment: Neutral
MLTX Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO , Nov. 18, 2025 /PRNewswire/ -- A securities class action, styled Bridgewood v. MoonLake Immunotherapeutics, et al.
Read More
MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: November 18, 2025 by: PRNewsWire
Sentiment: Neutral
BENSALEM, Pa., Nov. 18, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX).
Read More
Class Action Filed Against MoonLake Immunotherapeutics (MLTX) Over Securities Violations - Contact Levi & Korsinsky Today
Published: November 18, 2025 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - November 18, 2025) - If you suffered a loss on your MoonLake Immunotherapeutics (NASDAQ: MLTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/moonlake-lawsuit-submission-form?prid=177904&wire=5&utm_campaign=29 or contact Joseph E. Levi, Esq.
Read More
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact Levi & Korsinsky Before December 15, 2025 to Discuss Your Rights - MLTX
Published: November 18, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Nov. 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MoonLake investors who were adversely affected by alleged securities fraud between March 10, 2024 and September 29, 2025.
Read More
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX
Published: November 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of MLTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
Read More
MLTX INVESTOR ALERT: MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - RGRD Law
Published: November 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the MoonLake class action lawsuit – captioned Peters v. MoonLake Immunotherapeutics, No. 25-cv-08612 (S.D.N.Y.) – seeks to represent purchasers or acquirers of MoonLake Immunotherapeutics (NASDAQ: MLTX) common stock and charges MoonLake as well as certain of MoonLake's executives with violations of the Securities Exchange Act of 1934.
Read More
MoonLake: Ignore The Panic, Catch The Upside
Published: November 18, 2025 by: Seeking Alpha
Sentiment: Positive
MoonLake Immunotherapeutics is rated Buy, with sonelokimab having multiple dermatology and rheumatology indications. MLTX's VELA-1 trial succeeded, and VELA-2's statistical miss was due to elevated placebo response, not drug failure; combined analysis remains highly significant. Regulatory precedent, a strong financial runway into 2027, and multiple upcoming catalysts support a compelling asymmetric risk-reward profile for MLTX.
Read More
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit
Published: November 17, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Nov. 17, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline. So what: If you purchased MoonLake common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
ROSEN, SKILLED INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - MLTX
Published: November 17, 2025 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - November 17, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline. SO WHAT: If you purchased MoonLake common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
MLTX SECURITIES ALERT: BFA Law Notifies MoonLake Immunotherapeutics Investors of Important December 15 Securities Class Action Deadline
Published: November 17, 2025 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - November 17, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/moonlake-immunotherapeutics-class-action-lawsuit.
Read More
About MoonLake Immunotherapeutics (MLTX)
- IPO Date 2020-10-20
- Website https://www.moonlaketx.com
- Industry Biotechnology
- CEO Jorge Santos da Silva
- Employees 100